Ascendis Pharma reported positive two-year data for achondroplasia treatment. Data from the ApproaCH trial, announced on March 16, showed consistent growth improvement in children with achondroplasia using TransCon CNP. Further improvement in body proportionality was observed during the second year of weekly treatment.
